Scientific Opinion on the substantiation of a health claim related to Lactobacillus rhamnosus GG and maintenance of defence against pathogenic gastrointestinal microorganisms pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Tabs

Article
Panel on Dietetic Products, Nutrition and Allergies
EFSA Journal
EFSA Journal 2011;9(6):2167 [19 pp.].
Possible conflict of interest
One member of the Panel did not participate in the discussion on the subject referred to above because of potential conflicts of interest identified in accordance with the EFSA policy on declarations of interests
doi
10.2903/j.efsa.2011.2167
Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen
Acknowledgements

The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen for the preparatory work on this scientific opinion

Contact
Type
Opinion of the Scientific Committee/Scientific Panel
On request from
Competent Authority of Finland
Question Number
EFSA-Q-2010-01028
Adopted
13 May 2011
Published in the EFSA Journal
1 June 2011
Affiliation
European Food Safety Authority (EFSA), Parma, Italy
Note
Abstract

Following an application from Valio Ltd., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Finland, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to Lactobacillus rhamnosus GG (LGG) and maintenance of defence against pathogenic gastrointestinal (GI) microorganisms. LGG is sufficiently characterised. The Panel considers that the health claim refers to the defence against GI pathogens in the general population without GI infections and does not include the treatment of GI infections. Maintenance of defence against pathogenic GI microorganisms is a beneficial physiological effect. Only one out of five human intervention studies showed an effect of LGG consumption on the development of GI infections, two human intervention studies did not show an effect of LGG consumption on the stimulation of protective immune responses after oral (viral) vaccination and, in the absence of evidence for an effect of LGG consumption on the development of GI infections in the general population, studies on the treatment of GI infections, on diarrhoea during antibiotic use, or mechanistic studies, cannot be used as a source of data for the scientific substantiation of the health claim. The Panel concludes that a cause and effect relationship has not been established between the consumption of LGG and maintenance of defence against pathogenic gastrointestinal microorganisms.

Keywords
Lactobacillus rhamnosus GG, gastrointestinal infections, pathogens, acute diarrhea, health claims
Print on demand
Number of Pages
19